Companies › Axter Therapeutics (Beijing)
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AXT-1003 | – | Phase 1 | Non-Hodgkin Lymphoma; mCRPC | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06484985 | AXT-1003 | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT07897071 | AXT-1003 | Phase 1 | mCRPC | Oncology | Aug 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.